Small gene, big number, many effects

Blood

Volumn 120, Issue 2, 2012, Pages 240-241

  Calin, George A ^a   Konopleva, Marina ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAALC PROTEIN; CD135 ANTIGEN; MEMBRANE PROTEIN; MICRORNA; MICRORNA 107; MICRORNA 20A; MICRORNA 221; MICRORNA 222; MICRORNA 223; MICRORNA 3151; NUCLEOPHOSMIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CELL DIFFERENTIATION; CORRELATION ANALYSIS; CYTOGENETICS; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SCREENING; HEMATOPOIETIC CELL; HUMAN; LEUKEMIA REMISSION; MUTATIONAL ANALYSIS; NOTE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 84864141232     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-427393     Document Type: Note

References (11)

1. Eisfeld A-K, Marcucci G, Maharry K, et al. miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood. 2012;120(2):249-258.
2. Spizzo R, Nicoloso MS, Croce CM, Calin GA. Snap-Shot: MicroRNAs in cancer. Cell. 2009;137(3):586.
3. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer.2011;11(11):849-864.
4. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet.2012;13(5):358-369.
5. Stark MS, Tyagi S, Nancarrow DJ, et al. Characterization of the melanoma miRNAome by deep sequencing. PLoS One. 2010;5(3):e9685.
6. Schotte D, Moqadam FA, Lange-Turenhout EA, et al. Discovery of new microRNAs by small RNAome deep sequencing in childhood acute lymphoblastic leukemia. Leukemia.2011;25(9):1389-1399.
7. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-1918. (Pubitemid 351620111)
8. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
9. Marcucci G, Radmacher MD, Maharry K, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1919-1928. (Pubitemid 351620112)
10. Schwind S, Marcucci G, Maharry K, et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood.2010;116(25):5660-5669.
11. Heuser M, Berg T, Kuchenbauer F, et al. Functional role of BAALC in leukemogenesis. Leukemia. 2012;26(3):532-536.